Medisse, an Amersfoort and Enschede, the Netherlands-based biomaterials company, closed an undisclosed amount of equity financing.
The round was led by BioGeneration Ventures and Crédit Agricole Private Equity.
The company develops resorbable implants for soft tissue applications based on a patented flexible polymer platform. The financing will allow Medisse to speed up the development and global commercialization of its first products, FlexiSurge Mesh and FlexiSurge Barrier. As stated by Sandra de Vos, CEO of the company, the proceeds will also be used for developing other devices using the FlexiSurge material.
Wil Hazenberg from BioGeneration Ventures and Emmanuelle Coutanceau from Crédit Agricole Private Equity will join the company’s board of directors.